Peter S Kim bought $35k of TRDA
director at Entrada Therapeutics, Inc.. 2,732 shares at an average of $12.81, traded Mar 19, 2024, filed Mar 21, 2024.
Score components
- +15RoleDirector
- +6Trade size$35k at market
- +3Relative to holdingsHoldings up 6%
- +4Price context29% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689375-24-000018, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 19, 2024 | POpen-market purchase Common Stock | +900 | $12.66 | $11k | 47,944 | Mar 21, 2024 |
| Mar 20, 2024 | POpen-market purchase Common Stock | +1,128 | $12.66 | $14k | 49,072 | Mar 21, 2024 |
| Mar 21, 2024 | POpen-market purchase Common Stock | +704 | $13.24 | $9,318 | 49,776 | Mar 21, 2024 |
Related signals
Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $1.9M 259,837 shares | -6% | |
| 45Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $1.9M 259,837 shares | -6% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $616k 86,914 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $616k 86,914 shares | -2% | |
| 37Weak | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $432k 62,811 shares | -2% | |
| 48Moderate | Entrada Therapeutics, Inc. | Kush Parmar director | $1.1M 155,255 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.